Actively Recruiting
PSMA PET for Treatment Response evaLuation of systemIC Therapies in prostAte caNcer (PELICAN)
Led by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Updated on 2026-02-20
1300
Participants Needed
4
Research Sites
473 weeks
Total Duration
On this page
Sponsors
I
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Lead Sponsor
O
Ospedale Policlinico San Martino
Collaborating Sponsor
AI-Summary
What this Trial Is About
This prospective clinical study aims to evaluate the predictive power of PSMA PET imaging in patients with advanced prostate cancer who are receiving systemic drug therapies. The primary goal is to identify prognostic factors derived from PSMA PET imaging. These factors include the number of cancer lesions, the size of the tumor, and measurements known as SUVmax and SUVmean. By identifying these factors, the investigators aim to better group patients and predict those who may have a less favorable outcome. While PSMA PET imaging is highly accurate in locating cancer sites within the body, its ability to predict treatment response has not yet been thoroughly studied in a prospective manner for this patient population. This study will assess the predictive role of PSMA PET imaging and its ability to forecast treatment response across a range of systemic therapies, including hormone therapy and chemotherapy, in patients with both hormone-sensitive (HSPC) and castration-resistant (CRPC) prostate cancer.
CONDITIONS
Official Title
PSMA PET for Treatment Response evaLuation of systemIC Therapies in prostAte caNcer (PELICAN)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histological diagnosis of advanced prostate cancer (excluding neuroendocrine carcinoma)
- Patients undergoing PSMA PET for pre-treatment disease staging
- Candidates to receive one or more systemic therapies, including abiraterone, enzalutamide, apalutamide, darolutamide, docetaxel, cabazitaxel, olaparib, radiotherapy, lutetium-177-PSMA, or actinium-225-PSMA
- Signed informed consent for study participation and data handling
You will not qualify if you...
- Unable to remain supine and still for PET/CT image acquisition
- Prostate cancer with a significant neuroendocrine component
- Presence of another concurrent malignancy except non-melanoma skin cancer
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Italy, Italy, 40138
Actively Recruiting
2
Azienda Ospedaliera Santa Croce e Carle - ospedale Santa Croce
Cuneo, Italy, Italy, 12100
Actively Recruiting
3
U.O. Medicina Nucleare, IRCCS Ospedale Policlinico San Martino
Genova, Italy, Italy, 16131
Actively Recruiting
4
UOC Medicina Nucleare, AOU Policlinico G.Martino
Messina, Italy, Italy, 98125
Actively Recruiting
Research Team
A
Andrea Farolfi, MD
CONTACT
A
Andrea Di Giorgio, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here